Chronic urticaria (CU) is a dermatological condition characterized by recurrent wheals (hives), angioedema (deep tissue swelling), or both, persisting for over 6 weeks. 1 Unlike acute urticaria, which ...
Please provide your email address to receive an email when new articles are posted on . Barzolvolimab is an anti-KIT monoclonal antibody, and mast cells need KIT to survive. Weekly hive and itch ...
Please provide your email address to receive an email when new articles are posted on . Barzolvolimab binds receptor tyrosine kinase KIT to inhibit its activity, which mast cells need for survival.
An update to the guidelines for urticaria management was published, involving collaboration from various international ...
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria
REDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the ...
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...
HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in ...
Celldex Therapeutics (NASDAQ:CLDX) executives used an appearance at H.C. Wainwright’s annual Inflammation and Skin Disease ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved ...
Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results